Heidelberg Pharma Modifies Royalty Agreement with HealthCare Royalty and Soleus Capital

Heidelberg Pharma AG has announced an amendment to its royalty purchase agreement with HealthCare Royalty (HCRx) and a new participation from Soleus Capital. This amendment permits partial monetization of future royalties from sales of Telix Pharmaceuticals’ imaging agent, TLX250-Px. Heidelberg Pharma will receive USD 20 million upfront from Soleus Capital, pending customary closing conditions. Soleus Capital will provide an additional USD 25 million upon FDA approval of TLX250-Px.

The original agreement with HCRx, signed in March 2024, involved royalties on TLX250-Px up to a capped amount, amended first in 2025. The current modification also increases this cap and introduces additional contractual changes without affecting HCRx's payments. The arrangement ensures financing until mid-2027 for Heidelberg Pharma.